SecBot SecBot
8-K ·Filed Jun 2, 2026

TVTX

Travere Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed5mo ago SEC0001193125-26-252474
8-K Item 1.01 + 5.02 (likely routine officer/director compensation agreement)
Actionable Insight ▲ Bullish

Monitor the HSR clearance and any updates on development timeline for civorebrutinib. The recent executive departure (May 21) could indicate management transition; watch for further changes or clarity on leadership. The deal adds pipeline value but increases near-term cash burn.

DirectionBullish
Confidencemedium
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$42.96
T+0 close · Jun 2, 2026 · via day close
Latest settled
+56.24%
T+60 · $67.12
Vs SPY
+55.12%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 2 $42.96entry
  2. T+1 · 6mo ago +5.21%α +5.94% · $45.20
  3. T+5 · 5mo ago +13.06%α +16.02% · $48.57
  4. T+20 · 5mo ago +31.15%α +32.71% · $56.34
  5. T+60 · 3mo ago +56.24%α +55.12% · $67.12

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Travere Therapeutics entered into a license and collaboration agreement with EverestMedicines for exclusive rights to develop and commercialize civorebrutinib (BTK inhibitor) outside China and Southeast Asia. Travere will pay $112.5M upfront with up to ~$1.03B in milestones and tiered royalties. The deal expands Travere's pipeline in immune-mediated kidney diseases but carries development and cash burn risks. A recent executive departure (8-K filed May 21) adds uncertainty around management continuity.

Key Financial Metrics

Deal Value
$112.5M
Deal Type
license

Key Facts

  • Exclusive license for civorebrutinib (EVER001), a BTK inhibitor, for all therapeutic uses outside China and parts of Southeast Asia
  • Upfront payment of $112.5 million to Everest
  • Potential milestones up to approximately $1.03 billion across up to five indications
  • Tiered royalties from high single-digit to double-digit percentages on net sales
  • Travere responsible for development and commercialization in the Territory; cost-sharing on global trials
  • Agreement subject to HSR waiting period and other customary conditions
  • Prior 8-K (May 21, 2026) disclosed an executive departure and equity plan amendment

Financial Impact

Upfront payment of $112.5 million, plus up to $1.03 billion in contingent milestones and tiered royalties

cashr&d_expenserevenue

Risk Factors

  • Cash burn from $112.5M upfront and ongoing development costs
  • Clinical and regulatory risks for civorebrutinib (still in development)
  • Potential management disruption from recent executive departure
  • Competition in BTK inhibitor space

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-252474
Document: 0001193125-26-252474-index-headers.html0001193125-26-252474
Document: 0001193125-26-252474-index.html0001193125-26-252474
Document: 0001193125-26-252474.txt0001193125-26-252474

Track record

21 reports on TVTX

Performance horizon

7 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +49.98% at T+60 after the Feb 28, 2026 report. 9 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
  2. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
  3. Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
  4. Nov 2, 202614d ago 8-K Bullish 6/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
  5. Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
  6. Jul 9, 202618w ago 8-K Neutral 2/10 Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
  7. Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
  8. Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
  9. Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
  10. Jun 2, 202623w ago 8-K Bullish 6/10 Viewing Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 7h 21m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 2, 2026